WO1994018921A1
(fr)
*
|
1993-02-26 |
1994-09-01 |
Santen Pharmaceutical Co., Ltd. |
Bouchon de sclerotique biodegradable
|
US5707643A
(en)
*
|
1993-02-26 |
1998-01-13 |
Santen Pharmaceutical Co., Ltd. |
Biodegradable scleral plug
|
US6063396A
(en)
*
|
1994-10-26 |
2000-05-16 |
Houston Biotechnology Incorporated |
Methods and compositions for the modulation of cell proliferation and wound healing
|
US6063116A
(en)
*
|
1994-10-26 |
2000-05-16 |
Medarex, Inc. |
Modulation of cell proliferation and wound healing
|
US6369116B1
(en)
|
1995-06-02 |
2002-04-09 |
Oculex Pharmaceuticals, Inc. |
Composition and method for treating glaucoma
|
US20060280774A1
(en)
*
|
1995-06-02 |
2006-12-14 |
Allergan, Inc. |
Compositions and methods for treating glaucoma
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US6153231A
(en)
*
|
1997-06-25 |
2000-11-28 |
Wm. Wrigley Jr. Company |
Environmentally friendly chewing gum bases
|
WO1999001156A1
(fr)
*
|
1997-07-02 |
1999-01-14 |
Santen Pharmaceutical Co., Ltd. |
Bouchons scleraux d'acide polylactique
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6726918B1
(en)
*
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
EP3167872B1
(en)
|
2000-07-05 |
2020-10-14 |
Allergan, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
US6719750B2
(en)
*
|
2000-08-30 |
2004-04-13 |
The Johns Hopkins University |
Devices for intraocular drug delivery
|
EP1621219A3
(en)
*
|
2000-11-29 |
2006-03-22 |
Allergan, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
AU2002236495B2
(en)
|
2000-11-29 |
2006-05-11 |
Allergan, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
US6713081B2
(en)
*
|
2001-03-15 |
2004-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Ocular therapeutic agent delivery devices and methods for making and using such devices
|
EP1380302B1
(en)
*
|
2001-03-28 |
2008-08-20 |
Santen Pharmaceutical Co., Ltd. |
Remedies for retina and choroid diseases containing steroids as the active ingredient
|
US20040137059A1
(en)
|
2003-01-09 |
2004-07-15 |
Thierry Nivaggioli |
Biodegradable ocular implant
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
AU2004237774B2
(en)
*
|
2003-05-02 |
2009-09-10 |
Surmodics, Inc. |
Implantable controlled release bioactive agent delivery device
|
US8246974B2
(en)
*
|
2003-05-02 |
2012-08-21 |
Surmodics, Inc. |
Medical devices and methods for producing the same
|
US20040253293A1
(en)
*
|
2003-06-16 |
2004-12-16 |
Afshin Shafiee |
Rate controlled release of a pharmaceutical agent in a biodegradable device
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
KR20060129246A
(ko)
|
2003-12-05 |
2006-12-15 |
컴파운드 쎄라퓨틱스, 인크. |
타입 2 혈관 내피 성장 인자 수용체의 억제제
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
AU2005209201B2
(en)
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
US20060018949A1
(en)
*
|
2004-04-07 |
2006-01-26 |
Bausch & Lomb Incorporated |
Injectable biodegradable drug delivery system
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US8512738B2
(en)
*
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US8529927B2
(en)
*
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
US8673341B2
(en)
*
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US20060182781A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Methods for treating ocular conditions with cyclic lipid contraining microparticles
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US7589057B2
(en)
|
2004-04-30 |
2009-09-15 |
Allergan, Inc. |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20070212395A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Allergan, Inc. |
Ocular therapy using sirtuin-activating agents
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US20050244472A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
WO2006002366A2
(en)
*
|
2004-06-24 |
2006-01-05 |
Surmodics, Inc. |
Biodegradable ocular devices, methods and systems
|
EP1773350B1
(en)
*
|
2004-07-12 |
2013-05-29 |
Allergan, Inc. |
Opthalmic compositions for treating ophthalmic conditions
|
AU2013221985B2
(en)
*
|
2004-07-12 |
2016-09-01 |
Allergan, Inc. |
Ophthalmic compositions and methods for treating ophthalmic conditions
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US20060189582A1
(en)
*
|
2004-11-17 |
2006-08-24 |
Mclaurin Joanne |
Compositions and methods for treatment of disorders of protein aggregation
|
US20100196509A1
(en)
|
2005-02-28 |
2010-08-05 |
Jonathan Braun |
Methods for Diagnosis and Treatment of Endometrial Cancer
|
US20060233858A1
(en)
*
|
2005-03-08 |
2006-10-19 |
Allergan, Inc. |
Systems and methods providing targeted intraocular drug delivery
|
US8318906B2
(en)
|
2005-04-15 |
2012-11-27 |
The Regents Of The University Of California |
EMP2 antibodies and their therapeutic uses
|
US7931909B2
(en)
|
2005-05-10 |
2011-04-26 |
Allergan, Inc. |
Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
|
JP2009511568A
(ja)
*
|
2005-10-13 |
2009-03-19 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
|
KR101430760B1
(ko)
*
|
2005-10-18 |
2014-08-19 |
알러간, 인코포레이티드 |
후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
EP2397148A3
(en)
|
2006-02-02 |
2012-04-25 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
WO2007129221A2
(en)
*
|
2006-02-17 |
2007-11-15 |
Waratah Parmaceuticals Inc |
Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
|
US20070197452A1
(en)
*
|
2006-02-17 |
2007-08-23 |
Mclaurin Joanne |
Treatment of amyloid-related diseases
|
JP2009529502A
(ja)
*
|
2006-03-09 |
2009-08-20 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物
|
US20070260203A1
(en)
*
|
2006-05-04 |
2007-11-08 |
Allergan, Inc. |
Vasoactive agent intraocular implant
|
US7981096B2
(en)
*
|
2006-05-12 |
2011-07-19 |
David Castillejos |
Optic nerve head implant and medication delivery system
|
WO2007134449A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Waratah Pharmaceuticals Inc. |
Screening methods for amyloid beta modulators
|
US8668676B2
(en)
*
|
2006-06-19 |
2014-03-11 |
Allergan, Inc. |
Apparatus and methods for implanting particulate ocular implants
|
ES2523640T3
(es)
|
2006-06-21 |
2014-11-28 |
Musc Foundation For Research Development |
Direccionamiento del factor H del complemento para el tratamiento de enfermedades
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US9039761B2
(en)
|
2006-08-04 |
2015-05-26 |
Allergan, Inc. |
Ocular implant delivery assemblies with distal caps
|
JP2010500064A
(ja)
|
2006-08-08 |
2010-01-07 |
フンダシオン イナスメット |
埋込み型光学システム、その開発および適用のための手順
|
WO2008034244A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Waratah Pharmaceuticals Inc. |
The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
|
JP5694664B2
(ja)
*
|
2006-09-29 |
2015-04-01 |
サーモディクス,インコーポレイティド |
生分解性眼用インプラント及び眼の病気を治療する方法
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US8586556B2
(en)
|
2006-11-03 |
2013-11-19 |
Allergan, Inc. |
Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
|
CA2670471A1
(en)
|
2006-11-22 |
2008-06-05 |
Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
US20100292157A1
(en)
*
|
2006-11-24 |
2010-11-18 |
Antonio Cruz |
Combination Treatments for Alzheimer's Disease and Similar Diseases
|
CA2670990A1
(en)
|
2006-12-01 |
2008-06-12 |
Allergan, Inc. |
Method for determining optimum intraocular locations for drug delivery systems
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
US8846073B2
(en)
|
2006-12-19 |
2014-09-30 |
Allergan, Inc. |
Low temperature processes for making cyclic lipid implants for intraocular use
|
CA2683580A1
(en)
*
|
2007-04-12 |
2008-10-23 |
Joanne Mclaurin |
Treatment of amyotrophic lateral sclerosis
|
US20110105626A1
(en)
*
|
2007-04-12 |
2011-05-05 |
Mclaurin Joanne |
Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
|
DK2148667T3
(da)
*
|
2007-04-12 |
2013-08-26 |
Waratah Pharmaceuticals Inc |
Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
|
CA2683546A1
(en)
*
|
2007-04-12 |
2008-10-23 |
Joanne Mclaurin |
Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
US20080292680A1
(en)
*
|
2007-05-14 |
2008-11-27 |
Sustained Nano Systems Llc |
Hypercompressed polymer particles for controlled release ophthalmic medications
|
US8231892B2
(en)
|
2007-05-24 |
2012-07-31 |
Allergan, Inc. |
Biodegradable drug delivery system
|
JP2011517314A
(ja)
|
2008-02-14 |
2011-06-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
Egfrに結合する操作されたタンパク質に基づく標的化された治療薬
|
JP4922213B2
(ja)
|
2008-03-11 |
2012-04-25 |
本田技研工業株式会社 |
燃料直噴エンジン
|
EP2799448A1
(en)
|
2008-05-22 |
2014-11-05 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
US8821870B2
(en)
|
2008-07-18 |
2014-09-02 |
Allergan, Inc. |
Method for treating atrophic age related macular degeneration
|
JP2012505162A
(ja)
*
|
2008-10-09 |
2012-03-01 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
黄斑変性症関連障害を処置するためのscyllo−イノシトールの使用
|
ES2940466T3
(es)
|
2008-11-10 |
2023-05-08 |
Alexion Pharma Inc |
Métodos y composiciones para tratar trastornos asociados al complemento
|
US9095506B2
(en)
|
2008-11-17 |
2015-08-04 |
Allergan, Inc. |
Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
|
US8034813B2
(en)
|
2008-11-18 |
2011-10-11 |
Bausch & Lomb Incorporated |
Polymorphs of brimonidine pamoate
|
US9943402B2
(en)
|
2008-11-20 |
2018-04-17 |
Insight Innovations, Llc |
Micropatterned intraocular implant
|
MX2011005272A
(es)
*
|
2008-11-20 |
2011-06-21 |
Insight Innovations Llc |
Sistema de implante intraocular biocompatible biodegradable.
|
US8551167B2
(en)
|
2008-11-20 |
2013-10-08 |
Insight Innovations, Llc |
Intraocular implant cell migration inhibition system
|
US20120232649A1
(en)
|
2008-11-20 |
2012-09-13 |
Insight Innovations, Llc |
Intraocular Lens Cell Migration Inhibition System
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
US9308070B2
(en)
|
2008-12-15 |
2016-04-12 |
Allergan, Inc. |
Pliable silk medical device
|
US8545554B2
(en)
*
|
2009-01-16 |
2013-10-01 |
Allergan, Inc. |
Intraocular injector
|
MX2011008936A
(es)
|
2009-02-24 |
2011-09-21 |
Alexion Pharma Inc |
Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
|
US20110111031A1
(en)
*
|
2009-04-20 |
2011-05-12 |
Guang-Liang Jiang |
Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
|
AU2010264520A1
(en)
|
2009-06-23 |
2012-01-19 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
MX361709B
(es)
|
2009-11-09 |
2018-12-07 |
Allergan Inc |
Composiciones y metodos para estimular el crecimiento del cabello.
|
EP2501409A4
(en)
|
2009-11-20 |
2015-02-18 |
Univ California |
EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) AND PROLIFERATIVE VITREORETINOPATHY (PVR)
|
WO2011103599A2
(en)
|
2010-02-19 |
2011-08-25 |
The Regents Of The Universith Of California |
Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
|
SG185383A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
JP6023703B2
(ja)
|
2010-05-26 |
2016-11-09 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
|
KR20130036276A
(ko)
|
2010-06-22 |
2013-04-11 |
더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 |
보체 결합 3의 C3d 조각에 대한 항체들
|
US9447187B2
(en)
|
2011-02-03 |
2016-09-20 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
US9308355B2
(en)
|
2012-06-01 |
2016-04-12 |
Surmodies, Inc. |
Apparatus and methods for coating medical devices
|
US9827401B2
(en)
|
2012-06-01 |
2017-11-28 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
JP2015535212A
(ja)
|
2012-08-17 |
2015-12-10 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
補体活性化を検出するための組成物および方法
|
JP6511401B2
(ja)
|
2013-02-15 |
2019-05-15 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
持続型薬物送達インプラント
|
US9637534B2
(en)
|
2013-03-13 |
2017-05-02 |
Genzyme Corporation |
Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
|
US20160051673A1
(en)
|
2013-03-29 |
2016-02-25 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
WO2014179568A2
(en)
|
2013-05-02 |
2014-11-06 |
Odin Biotech |
Two-layer ocular implant
|
EA034870B1
(ru)
|
2013-08-07 |
2020-03-31 |
Алексион Фармасьютикалз, Инк. |
Белковые биомаркеры атипичного гемолитического уремического синдрома
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
CN114057857A
(zh)
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
EP3215176A4
(en)
|
2014-10-03 |
2018-05-23 |
Ntercept, LLC |
Compositions and methods for inhibiting the biological activity of soluble biomolecules
|
WO2016123454A1
(en)
|
2015-01-29 |
2016-08-04 |
Board Of Trustees Of Miching State University |
Cryptic polypeptides and uses thereof
|
US10627415B2
(en)
|
2015-03-12 |
2020-04-21 |
Board Of Trustees Of Michigan State University |
Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
WO2017176762A1
(en)
|
2016-04-06 |
2017-10-12 |
Nanotics, Llc |
Particles comprising subparticles or nucleic acid scaffolds
|
EP3541408A4
(en)
|
2016-11-15 |
2020-06-24 |
The Schepens Eye Research Institute, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
NZ760841A
(en)
|
2017-07-11 |
2024-02-23 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
DK3658184T3
(da)
|
2017-07-27 |
2023-11-27 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
CA3072673A1
(en)
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
|
WO2019036605A2
(en)
|
2017-08-17 |
2019-02-21 |
Massachusetts Institute Of Technology |
MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
|
AU2018329850A1
(en)
|
2017-09-08 |
2020-04-23 |
Bristol-Myers Squibb Company |
Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
US11260048B2
(en)
|
2017-10-03 |
2022-03-01 |
The Schepens Eye Research Institute, Inc. |
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
AU2018369784B2
(en)
|
2017-11-14 |
2023-06-01 |
Massachusetts Eye And Ear Infirmary |
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019178269A2
(en)
|
2018-03-14 |
2019-09-19 |
Surface Oncology, Inc. |
Antibodies that bind cd39 and uses thereof
|
WO2019183499A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
CA3093715A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
WO2019226617A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
EP3833442A2
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antibodies that bind cd277 and uses thereof
|
EP3833443A1
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigen binding agents that bind cd277 and uses thereof
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
WO2020112816A1
(en)
|
2018-11-29 |
2020-06-04 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
US20220111047A1
(en)
|
2019-01-16 |
2022-04-14 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
WO2020163782A2
(en)
|
2019-02-08 |
2020-08-13 |
The Uab Research Foundation |
Immunotherapy for the treatment and prevention of inflammatory bowel disease
|
US11819590B2
(en)
|
2019-05-13 |
2023-11-21 |
Surmodics, Inc. |
Apparatus and methods for coating medical devices
|
KR200493373Y1
(ko)
|
2019-05-28 |
2021-03-17 |
김정모 |
보호펜스
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
EP4034559A1
(en)
|
2019-09-25 |
2022-08-03 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
JP2022554175A
(ja)
|
2019-10-23 |
2022-12-28 |
チェックメイト ファーマシューティカルズ, インコーポレイテッド |
合成rig-i様受容体アゴニスト
|
US11459389B2
(en)
|
2019-10-24 |
2022-10-04 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human CD161
|
WO2021231720A1
(en)
|
2020-05-15 |
2021-11-18 |
Alexion Pharmaceuticals, Inc. |
Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
|
KR102506897B1
(ko)
|
2020-06-25 |
2023-03-06 |
김정모 |
회전식 부착부재가 구비된 보호펜스
|
MX2023013149A
(es)
|
2021-05-07 |
2023-11-28 |
Surface Oncology Llc |
Anticuerpos anti-il-27 y usos de estos.
|
EP4348263A1
(en)
|
2021-05-28 |
2024-04-10 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
WO2023105417A1
(en)
|
2021-12-06 |
2023-06-15 |
Breye Therapeutics Aps |
Danegaptide formulation for applicatoin in the eye
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024054436A1
(en)
|
2022-09-06 |
2024-03-14 |
Alexion Pharmaceuticals, Inc. |
Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
|